Literature DB >> 1653573

Prevention and management of drug-induced peripheral neuropathy.

L L Olesen1, T S Jensen.   

Abstract

When symptoms of peripheral neuropathy appear, the possibility that they have been induced by drugs should be considered. A large number of drugs of all kinds, several of which are considered indispensable, have been implicated in peripheral neuropathy. A list of some of these drugs is provided. Neuropathy is a universal and dose-limiting factor during treatment with vinca alkaloids, but is otherwise a rare complication of drug therapy. Drug-induced peripheral neuropathy is almost always due to a dose-dependent primary axonal degeneration caused either by toxic reactions or by metabolic changes in neurons or their surroundings. The use of drugs should be restricted, especially in patients with a risk for development of neuropathy or with already existing neuropathy, e.g. patients with hepatic or renal failure, diabetes mellitus, or malnutrition. Patients should be given vitamins, prophylactically or therapeutically, which will sometimes allow a treatment to be continued. In other cases of drug-induced neuropathy the drug should be stopped. Reversal depends on the severity of the neuropathy, intensity and duration of the treatment and existence of causative cofactors, but generally the prognosis is good. While waiting for recovery physiotherapy is of importance, and when paraesthesia and pain are troublesome the patient should be treated with carbamazepine, imipramine or lidocaine (lignocaine).

Entities:  

Mesh:

Year:  1991        PMID: 1653573     DOI: 10.2165/00002018-199106040-00007

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  107 in total

1.  Polyneuropathy after perhexiline maleate therapy.

Authors:  F Lhermitte; M Fardeau; F Chedru; J Mallecourt
Journal:  Br Med J       Date:  1976-05-22

2.  Peripheral neuropathy with ethambutol.

Authors:  P Tugwell; S L James
Journal:  Postgrad Med J       Date:  1972-11       Impact factor: 2.401

Review 3.  [Side effects of drugs. 4. Drug induced polyneuropathies and myopathies].

Authors:  B Johansson
Journal:  Lakartidningen       Date:  1969-12-15

4.  Gold neuropathy.

Authors:  J C Walsh
Journal:  Neurology       Date:  1970-05       Impact factor: 9.910

5.  Intravenous 2-chloroprocaine in treatment of chronic pain.

Authors:  M Schnapp; K S Mays; W C North
Journal:  Anesth Analg       Date:  1981-11       Impact factor: 5.108

6.  Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.

Authors:  D Hadley; H W Herr
Journal:  Cancer       Date:  1979-12       Impact factor: 6.860

7.  Hexamethylmelamine. An evaluation of its role in the therapy of cancer.

Authors:  S S Legha; M Slavik; S K Carter
Journal:  Cancer       Date:  1976-07       Impact factor: 6.860

8.  A trial of amitriptyline and fluphenazine in the treatment of painful diabetic neuropathy.

Authors:  C M Mendel; R F Klein; D A Chappell; W H Dere; B J Gertz; J H Karam; T N Lavin; C Grunfeld
Journal:  JAMA       Date:  1986-02-07       Impact factor: 56.272

9.  Chloroquine neuromyotoxicity. Clinical and pathologic perspective.

Authors:  M L Estes; D Ewing-Wilson; S M Chou; H Mitsumoto; M Hanson; E Shirey; N B Ratliff
Journal:  Am J Med       Date:  1987-03       Impact factor: 4.965

Review 10.  Disorders of gastrointestinal motility associated with diabetes mellitus.

Authors:  M Feldman; L R Schiller
Journal:  Ann Intern Med       Date:  1983-03       Impact factor: 25.391

View more
  2 in total

Review 1.  Practical aspects of drug treatment in elderly patients with mobility problems.

Authors:  J H Thwaites
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  Peripheral Neuropathy under Oncologic Therapies: A Literature Review on Pathogenetic Mechanisms.

Authors:  Mariarita Laforgia; Carmelo Laface; Concetta Calabrò; Simona Ferraiuolo; Valentina Ungaro; Domenico Tricarico; Cosmo Damiano Gadaleta; Patrizia Nardulli; Girolamo Ranieri
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.